Cullinan Oncology News and Activities

Cullinan Oncology is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Cullinan Oncology is a company listed under the stock ticker CGEM (US).

View the org chart displaying its 22 main executives

Most searched biographies at Cullinan Oncology

• Nadim Ahmed, Chief Executive Officer and Director
• Tony Rosenberg, Director
• Mittie Doyle, Director

Create your alert
to follow the executive moves at Cullinan Oncology.

Cullinan Oncology has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Cullinan Oncology

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference | Cullinan Oncology, Inc.
• Cullinan Oncology to Participate in William Blair Biotech Focus Conference | Cullinan Oncology, Inc.
• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 | Cullinan Oncology, Inc.
• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting | Cullinan Oncology, Inc.
• Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting | Cullinan Oncology, Inc.
• Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference | Cullinan Oncology, Inc.
• Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results | Cullinan Oncology, Inc.
• View more press releases Close

Social media about Cullinan Oncology

• Cullinan Oncology on Wikipedia, Google News & Yahoo Finance
• Cullinan Oncology on LinkedIn, X (Twitter) & YouTube